XM does not provide services to residents of the United States of America.
G
G

Groupon

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Tempus AI stretches rally as co and SoftBank launch AI healthcare JV

BUZZ-Tempus AI stretches rally as co and SoftBank launch AI healthcare JV ** Shares of genetics testing firm Tempus AI TEM.O , backed by SoftBank 9984.T , up ~7% early Thurs, adding to ~10% gain in prior session ** SoftBank has launched joint venture with Tempus aiming to analyze personal medical data with artificial intelligence to come up with treatment recommendations, CEO Masayoshi Son told a briefing in Tokyo on Thurs ** The cos expected to each put $93 mln into the JV, which is anticipated
G

SoftBank-backed Tempus AI sinks to new post-IPO lows

BUZZ-SoftBank-backed Tempus AI sinks to new post-IPO lows ** Shares of Tempus AI TEM.O , genetics testing firm backed by SoftBank 9984.T , down 2.7% at $24.63 on Tues and now off ~33% from IPO price ** Stock drops as much as 9.6% to $22.89 on the session ** TEM shares on track to fall for fifth time in past six days since closing up nearly 9% at $40.25 in their Jun 14 debut ** Tempus, founded in 2015 and has yet to turn a profit, raised ~$411 mln by selling 11.1 mln shares at $37 , top end of ma
G

SoftBank-backed Tempus AI extends slump after strong listing

BUZZ-SoftBank-backed Tempus AI extends slump after strong listing Updates ** Shares of SoftBank 9984.T -backed Tempus AI TEM.O tumble as much as ~ 21 % to slump for the third straight session ** The genetics testing firm, led by Groupon GRPN.O co-founder Eric Lefkofsky, closed up 8.8% at $40.25 on its market debut on Friday, June 14 ** Shares fell 9.4% on Monday and 16.9% on Tuesday ** Tempus, which was founded in 2015 and is yet to post a profit, raised $410.7 mln by selling 11.1 mln shares at
G

SoftBank-backed Tempus AI extends slump after strong listing

BUZZ-SoftBank-backed Tempus AI extends slump after strong listing ** Shares of SoftBank 9984.T -backed Tempus AI TEM.O tumble as much as 20% to slump for the third straight session ** The genetics testing firm, led by Groupon GRPN.O co-founder Eric Lefkofsky, closed up 8.8% at $40.25 on its market debut on Friday, June 14 ** Shares fell 9.4% on Mon
G

SoftBank-backed Tempus AI tumbles well below IPO price

BUZZ-SoftBank-backed Tempus AI tumbles well below IPO price ** Shares of Tempus AI TEM.O , genetics testing firm backed by SoftBank 9984.T , down 16% at $30.65 on Tues in their third day of trading ** TEM, which shed ~9% on Mon, tumbles as low as $30.31 on the session ** Stock now >17% below $37 IPO price set late Thurs after co raised ~$411 mln by selling 11.1 mln shares ** TEM traded as high as $43.88 in debut on Fri before closing at $40.25 ** Co led by Groupon GRPN.O co-founder Eric Lefkofsk
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.